Detection of HIV-1 infection in vitro using NASBA: an isothermal RNA amplification technique.

Establishment of a sensitive infection assay for HIV-1 is essential for successful screening of antiviral agents and neutralizing antibodies. In this report, an infection assay is described which measures the expression of viral genomic RNA and spliced mRNA intermediates in infected cells by an amplification-based technique called NASBA. The extreme sensitivity of this method permits the detection of viral RNA in peripheral blood mononuclear cells (PBMC) within 48 h of infection by a low dose of virus. Similarly, spliced HIV-1 mRNA could be detected within 24 h of infection of CEM cells by HIV-1IIIB. This NASBA-based infection assay was shown to titer the neutralization of the HIV-1IIIB isolate by serum from an infected human and by a monoclonal antibody to gp120. Furthermore, the inhibitory effects of azidothymidine (AZT) and soluble CD4 on HIV-1IIIB infection were quantitated by this assay. The early detection of virus by NASBA minimizes the contribution of secondary infection, thereby permitting more accurate evaluation of antiviral agents and neutralizing antibodies. This assay may be useful for the study of infection of phenotypically distinct HIV-1 isolates, which differ in terms of their replication kinetics.

[1]  Huisman,et al.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex , 1988, Journal of virology.

[2]  D. van Strijp,et al.  NASBATM isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection , 1991 .

[3]  R Blumenthal,et al.  Quantitation of human immunodeficiency virus type 1 infection kinetics , 1993, Journal of virology.

[4]  D. Baltimore,et al.  Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4+ lymphocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Capon,et al.  The CD4-gp120 interaction and AIDS pathogenesis. , 1991, Annual review of immunology.

[6]  J. Albert,et al.  Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates , 1988, Journal of virology.

[7]  C. Cheng‐Mayer Biological and molecular features of HIV-1 related to tissue tropism. , 1990, AIDS.

[8]  M. Robert-Guroff,et al.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex , 1985, Nature.

[9]  D. van Strijp,et al.  Quantification of HIV-1 RNA in plasma using NASBA during HIV-1 primary infection. , 1993, Journal of virological methods.

[10]  M. Gonda,et al.  Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. , 1987, AIDS research and human retroviruses.

[11]  H. Schuitemaker,et al.  Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture , 1991, Journal of virology.

[12]  L. Ratner Molecular biology and pathogenesis of HIV infection , 1993 .

[13]  R. Gallo,et al.  Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[14]  L. Ratner,et al.  Alterations in spliced and unspliced HIV-1-specific RNA detection in peripheral blood mononuclear cells of individuals with varying CD4-positive lymphocyte counts. , 1993, AIDS research and human retroviruses.

[15]  M. Salimans,et al.  Rapid and simple method for purification of nucleic acids , 1990, Journal of clinical microbiology.

[16]  A. Fauci,et al.  Immunopathogenesis of HIV infection , 1991, Journal of acquired immune deficiency syndromes.

[17]  M A Fischl,et al.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[18]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[19]  C. Rinaldo,et al.  Human immunodeficiency virus isolates from asymptomatic homosexual men and from AIDS patients have distinct biologic and genetic properties. , 1991, Virology.